Compare · NVO vs PVLA
NVO vs PVLA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Palvella Therapeutics Inc. (PVLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PVLA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.38B, about 125.8x PVLA ($1.50B).
- Over the past year, NVO is down 44.1% and PVLA is up 292.8% - PVLA leads by 336.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for PVLA).
- NVO has more recent analyst coverage (25 ratings vs 15 for PVLA).
- Company
- Novo Nordisk A/S
- Palvella Therapeutics Inc.
- Price
- $42.19+2.89%
- $104.45-1.00%
- Market cap
- $188.38B
- $1.50B
- 1M return
- -8.44%
- -14.09%
- 1Y return
- -44.09%
- +292.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PVLA
- ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
- Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
- Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
- Chief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $475,631 worth of shares (4,302 units at $110.56) as part of a pre-agreed trading plan (SEC Form 4)
- Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
- Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
- Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events